Previous Organizing Committee
OCM Member
MD
Hawaii Institute for Health and Healing LLC , USA
Biography :

Dr Myles Suehiro completed his graduation from University of Colorado Boulder in 1965. He is a recipient of several fellowships and certification in Internal medicine including Fellowship in Anti-Aging Regenerative and Functional Medicine. He worked as an Assistant Professor at Charles R. Drew Postgraduate Medical School till 1986, after which he was appointed as the Director of I.C.U. at City View Hospital, Los Angeles and Medical Director at Cardio-Pulmonary Lab in 1990. He holds immensely vast experience in the field of medicine (more than 45 years) and is interested in the potential of treating rare disorders with the help of regenerative and functional medicine. At present he works as the Director of the Hawaii Institute for Health and Healing, LLC.

OCM Member
Senior Staff Scientist, Division of Molecular and Cellular Medicine
National Cancer Center Research Institute , Japan
Biography :

Dr. Yusuke Yamamoto completed his Ph.D. in Molecular Physiology from Waseda University, Japan in 2008. He further pursued his postdoctoral studies under the supervision of Prof. Frank McKeon and A/Prof. Wa Xian at Genome Institute of Singapore. Presently, he is working as a Senior Staff Scientist at National Cancer Center Research Institute, Japan. He has been interested in how adult stem cells maintain their stemness throughout the lifespan as well as identifying cell-of-origin in esophageal adenocarcinomas and high grade serous ovarian carcinoma, which are the most aggressive type of cancers with poor prognosis. With his outstanding research work, he has published more than 40 papers in peer-reviewed journals, including Nature and Cell and holds one US patent on ‘Nanobio device of imitative anatomy structure’ in 2010 while another one, ‘Novel Diagnosis and Therapeutic Targets for Cervical Cancer’ is in the pipeline. He has presented his various research work in 15 national and international conferences and is a member of The Molecular Biology Society of Japan, Japanese Cancer Association and The Japanese Biochemical Society.

Research Interest :

Mutational Spectrum of Barrett's Stem Cells suggests paths to initiation and progression of a precancerous lesion

OCM Member
Senior Research Associate, Division of Plastic Surgery
The university of British Columbia , Canada
Biography :

Dr. Yunyuan Li has completed his Ph.D. in 2005 from the University of Alberta, Canada. He is a currently a senior researcher at Burn and Wound Healing Research Laboratory at the University of British Columbia, Canada. His research interests were focused on the roles of hematopoietic cell-derived multi-potent stem cells in skin wound healing, hair follicle regeneration, and inflammation. Till now, Dr. Li has published over 40 articles in peer-reviewed journals.

Research Interest :

Hematopoietic cell-derived multi-potent stem cells in skin wound healing

OCM Member
Professor, Center for Stem Cell & Regenerative Medicine
University of Texas Health Science Center , USA
Biography :

Dr. Wa Xian received her Bachelor’s degree in Biochemistry from Nankai University in China and Ph.D. degree in Molecular Genetics at the University of Texas Graduate School of Biomedical Sciences in Houston, focusing on master regulator genes of cell proliferation and lineage specification during early neural development. The support of a DOD breast cancer fellowship enabled Dr. Xian’s postdoctoral studies with Prof. Jeffrey Rosen at the Baylor College of Medicine. There she used a combination of ligand-induced dimerization strategies and a mammary epithelial 3D culture system to address the role of fibroblast receptor tyrosine kinase signaling in the evolution of breast cancer. In 2008, Dr. Xian moved to Harvard Medical School under the direction of Prof. Christopher Crum, Director of Women’s and Perinatal Pathology at the Brigham and Women’s Hospital to study the origin and evolution of ovarian cancer. Dr. Xian continues to work very closely with Prof. Crum on the origins and chemotherapy resistance problem in high-grade ovarian cancer. In 2009, Dr. Xian was appointed Principal Investigator at the Institute of Medical Biology of the Agency for Science, Technology, and Research in Singapore, where she jointly oversaw a highly interactive group of postdoctoral fellows, graduate students, and research assistants with Prof Frank McKeon of the Genome Institute of Singapore devoted to the cloning of stem cells of regenerative tissues and using advanced technologies to understand the genetics of their self-renewal, commitment, and differentiation. In 2013, Dr. Xian returned to the US and initiated multiple projects related to inflammatory diseases and cancer with colleagues at the University of Connecticut Health Center. In 2015, Dr. Xian received the Rising Stars Award from the Cancer Prevention & Research Institute of Texas (CPRIT) and was recruited to the Institute of Molecular Medicine at the University of Texas Health Science Center in Houston.

Research Interest :

Biomarkers and Molecular imaging in gastrointestinal Cancer

OCM Member
Associate Professor, Biomedicine, Stem Cell & Regenerative Medicine
Edinburgh Medical School-Zhejiang International Campus, (ZJU) , China
Biography :

Professor Ahmed Hashash has completed his PhD from Manchester University, UK. He is a fellow of the California Institute of Regenerative Medicine (CIRM) and New York University Medical School (MSSM), USA. Prof. Ahmed Hashash worked as a senior biomedical research scientist at Mount Sinai School of Medicine of New York University and Children’s Hospital Los Angeles. He was Assistant Professor and Principal Investigator of Stem Cell & Regenerative Medicine at Keck School of Medicine and Ostrow School of Dentistry of The University of Southern California, USA. In 2016, Prof. Hashash has joined The University of Edinburgh, Edinburgh Medical School-Zhejiang International Campus, (ZJU) as Tenure-Track Associate Professor and Senior Principal Investigator of Biomedicine, Stem Cell & Regenerative Medicine. He is also adjunct Professor at the School of Basic Medical Science and School of Medicine, Zhejiang University. Prof. Hashash has several breakthrough discoveries in genes/enzymes that control stem cell behavior and regenerative medicine. He has published more than 25 papers in reputed international journals and serving as an editorial board member of repute. Prof. El-Hashash acts as a discussion leader at the prestigious Gordon Research Seminar/Conference in USA, and a Peer Reviewer/ International Extramural Review for The Medical Research Council (MRC) grant applications, London, UK. He is invited to speak at several international conferences in USA, Spain, Greece, Egypt and China. He is the editor or author of several books on stem cell and regenerative medicine.

Research Interest :

Stem Cell Therapy of Diseases & Cell and Developmental Biology

OCM Member
Associate Professor, Department of Biological Sciences
Clark Atlanta University , USA
Biography :

Bekir Cinar completed his Postdoctoral Fellowship, Boston Children’s Hospital, Harvard Medical School (HMS), Boston, MA (2002-2006) and Ph.D. from Department of Biochemistry and Molecular Genetics, School of Medicine University of Virginia, Charlottesville, VA (1995-2002), D.V.M., Veterinary Medical School, Ankara University, Ankara, Turkey (1987-1992). Currently he is working as Associate Professor, Department of Biological Sciences, Clark Atlanta University (CAU), Atlanta, GA 2015 to present. Presently, He is also member of the Center for Cancer Research and Therapeutic Development at CAU and a member of the NCI-designated Winship Comprehensive Cancer Center at Emory University. Prior to joining CAU, Dr. Cinar was Assistant Professor of Medicine-Hematology/Oncology and Biomedical Sciences at Cedars-Sinai Medical Center, where he was a member of Samuel Oschin Comprehensive Cancer Institute.

Research Interest :

His research focus is on Signal Transduction, gene Expression, genomics, Proteomics, Bioinformatics, 3DCell Cultures

OCM Member
CEO
WAMS(The World Academy of Medical Sciences) , Mexico
Biography :

Mr. De la Parra is an entrepreneur focused on Information Technology, Education and Health. He is creative and results-driven and has 16+ years of Digital Strategy experience in architecture and implementation. Mr. De la Parra is the COO and Co-founding Partner at The Solomon Brokerage Firm. He currently leads as CEO at Mass Media Division & De la Parra Mobile Solutions, while also being the President of PetroM Renewable, VP of Operations & Strategy at PetroM Logistics, both divisions of PetroM Corp. Former COO & Co-founder at RegenerAge® Clinic & RegenerAge® Beauty & a member of the Board of Advisors. Former CEO & Founder at Astrum Salud Móvil and its Telemedicine service Astrum Móvil, former Digital Strategy Director & Co-founder at Dr. Jois®, BiorganicAging®, What Skin Needs™/WSN International Pty. Ltd. He also served as a member of the Board of Advisors and is former CMO at ReAnima Advanced Biosciences and former Digital Media Director at Bioquark, Inc. Within the academic and educational fields, Mr. De la Parra acted as the Executive Vice President: Executive Chairman of the WAMS Mobile Health Division, WAMS Chief Coordinating Officer, a member of the WAMS Executive Council (WAMS Executive Board), a member of the WAMS Education & Training Board (ETB), a member of the WAMS Editorial Board, an Honorary Member of the Academy Faculty FWAMS, an Honorary Fellow of the Academy & is also a Senior Partner at WAMS, The World Academy of Medical Sciences. He is also an Advisory Board member, functioned as the Chief Operating Officer and is a Co-founding Partner at The Reprogramming Medicine Association. Mr. De la Parra is also a member of the National Introducing Brokers Association and a part of the National Biofuel Board, (Alliance Program), also being the founder and former Board of Directors member of Astrum Fundación, an Advisory Board member of the Lifeboat Foundation, an Advisory Board member of the Future Worlds Center - Cyprus Neuroscience & Technology Institute (Senior TV Program), a Federated member of the International Longevity Alliance, and volunteered as Digital Strategy adviser at the Major Mouse Testing Program. He is also a member of the Web Committee at the Life Extension Advocacy Foundation / Lifespan.io and has volunteered with SENS Research Foundation for the OncoSENS Program in Digital Strategy. Alejandro De la Parra Solomon is on Google+, Facebook, and on LinkedIn.

Research Interest :

Neuroscience, Regenerative Medicine, Continued Medical Education, Information & Communications Technology, Biotechnology, Social Development

OCM Member
Professor, M. D. Anderson Cancer Center
The University of Texas , USA
Biography :

Dr. Jinsong Liu is a professor with tenure in the Department of Pathology at The University of Texas M. D. Anderson Cancer Center since 2009. He received his medical degree from Shanghai Medical University 1983 and completed his Ph.D. from Case Western Reserve University in 1991, and post-doctoral training at the University of Michigan in 1993, pathology residency and surgical pathology fellowship training at New York University in 1999. Dr. Liu is an internationally recognized for his expertise in diagnostic pathology and research achievements in ovarian cancer. Dr. Liu has co-authored 213 original publications and has been an editorial member of several reputable journals.

Research Interest :

His research interest has focused on the mechanisms of epithelial tumorigenesis, inflammation, and cancer stem cells.

OCM Member
University of New South Wales , Australia
Biography :

A/Prof Yong Li obtained his PhD degree at University of New South Wales (UNSW) Sudney, Australia in 2000. He became Cancer Research Group leader in 2006, and is an established cancer researcher, with expertise in cancer biomarker discovery, radiation biology, target cancer therapy and cancer metastasis. He was awarded an NHMRC Career Development Fellowship (Level 2) in 2010-2014; and an NHMRC Achievement Award (ranked No.1 in the industry fellow) in 2011. He was promoted to an Associate Professor in the Faculty of Medicine, UNSW since 2011, and a Principal Scientific Officer by the South Eastern Sydney Local Health District (SESLHD) since 2012. A/Prof Li has more than 100 career publications in cancer research area since 1999.

Research Interest :

Associate Professor Li’s research is aimed at a): To investigate novel biomarkers from human body fluids and tissues, cancer cell lines and animal models for cancer diagnosis and monitoring cancer progression; b): To investigate the mechanisms of cancer metastasis and chemo-/radio-resistance; c): To use targeted cancer therapy and combination therapy to control metastatic and therapeutic resistant cancers.

OCM Member
StemRx Bioscience Solutions Pvt. Ltd. , India
Biography :

Dr. Mahajan completed his masters in General Surgery from Marathwada University, Maharashtra and went on to pursue Diploma in Urology at the University of Vienna, Austria. In a career changing move, after three decades of being a successful general and uro-surgeon, he started his brainchild-StemRx Bioscience Solutions Pvt. Ltd. in the year 2011. This was to focus on in-depth research in the field of Regenerative Medicine and Cell Based Therapy which he believes is the solution to address the limitations of conventional therapeutic modalities. To this effect, he underwent and continues to undergo intensive training in the United States. He has devised personalized treatment protocols in cell-based therapy for more than 75 health conditions. Dr. Mahajan is a Life member and Joint Secretary of The Stem Cell Society of India as well as Vice President of Anti-Aging Foundation, Delhi and Scientific National Advisor, Indian Stem Cell Study Group. He has been appointed as Hon. Associate Professor of Regenerative Medicine and Cell Based Therapy at Dr. R N Cooper Hospital, Mumbai and Faculty for MD Transfusion Medicine at KEM Hospital, Mumbai. Examiner for various fellowship courses with D.Y. Patil Institute, Kolhapur. Dr. Mahajan’s academic collaborations include being a Member of board of studies in ITM University, Raipur / MUHS, for PhD courses, M.Sc. and Fellowship Programs in stem cells and regenerative medicine. Among his international associations, a clinical trial in collaboration with the Ohio State University, USA on Cell Based Therapy for Avascular Necrosis is noteworthy, wherein Dr. Mahajan is a Principal Investigator. He is also a principal investigator in collaboration with Indiana University, Indianapolis under the guidance of Dr Chandan Sen to conduct the first human clinical trials using TNT technology in India. His recent international ventures include extension of StemRx facilities in Africa and collaboration with an organization in Japan to launch NK cell (cancer immunotherapy) technology for solid tumours in India. His company StemRx is also working on CAR-T cells technology in India. He has published an international patent for treatment of Avascular Necrosis using Regenerative Medicine approach and Indian patents for Avascular Necrosis, Ankylosing Spondylitis, Ischemic-tolerance Mesenchymal Stem Cell treatment/technology and isolation of dental pulp stem cells. He has 13 paper publications to his credit. Dr Mahajan has also been appointed by Government of India and Government of Maharashtra as consultant and panel doctor with the director general of shipping and labour department. Dr Mahajan is also associated with scholarly Journals for reviewing articles / research publication. Some of these are • Member, Editorial Board – ASMI • Member Editorial Board for reviewing scholarly articles, Gavin Publishers • Member Health Council – Head Hunt • Expert Reviewer – Journal of Scientific Research & Report • Expert Reviewer – British Journal of Medicine & Medical Research His drive to achieve tangible outcomes in research and therapy has earned him recognition and several awards in the field of healthcare—Paris Appreciation Award and National Awards for Excellence in Healthcare (Clinical Research category) for 2 consecutive years (2016 & 2017) to name a few. Recently he has also been featured in the Forbes Healthcare magazine for his pioneering work in the field of stem cell

Research Interest :

Regenerative Medicine and Stem Cell

OCM Member
Director, Director
West Virginia University , USA
Biography :

Ming Pei completed his PhD from Beijing University, China and Postdoc training from Harvard-MIT Division of Health Sciences and Technology, USA. Currently he is a tenured Professor and Director of Stem Cell and Tissue Engineering Laboratory in the Department of Orthopaedics, West Virginia University, USA. He has over 100 publications that have been cited over 3100 times, and his publication H-index is 32 and has been serving as an editorial board member of reputed Journals.

Research Interest :

Stem cells, Tissue engineering, Biomaterials

OCM Member
Department of Zoology, University of cambridge , United Kingdom
Biography :

Joo-Hyeon Lee was fascinated by stem cell research through Ph.D. studies under the supervision of Prof. Daesik Lim in KAIST, Korea. She then joined Prof. Carla Kim’s laboratory at Harvard Medical School where she became interested in the study of adult lung stem cells. She established her own research group at the Cambridge Stem Cell Institute in 2016 and focuses on understanding cellular behavior and regulatory networks of adult stem and niche cells. Joo-Hyeon is currently Faculty member at the Department of Physiology, Development, and Neuroscience, University of Cambridge and was recently awarded the Royal Society and Wellcome Trust Sir Henry Dale Fellowship and ERC starting grant.

Research Interest :

Lee lab applies mouse genetics, ex vivo organoid co-cultures, live imaging, single-cell molecular analysis and mathematic modelling to define the identity and heterogeneity of diverse epithelial progenitor and mesenchymal populations, understand the key stem-mesenchymal interactions and the precise mechanisms that maintain tissue homeostasis and regeneration. Specifically, they are asking how the quiescent state is maintained and becomes activated, how cell fate is determined, and how niches develop and remodel in lung homeostasis, injury repair and early tumorigenesis.

OCM Member
Marseille Cancer Research Centre , France
Biography :

Claire Acquaviva obtained her PhD at Montpellier University working on the proteolytic regulation of Fos transcription factors in Dr. Marc Piechaczyk’s laboratory at the Institute of Molecular Genetics of Montpellier (IGMM). She worked as a post-doc in Jonathon Pines’ laboratory at the Gurdon Institute in Cambridge (UK) on the regulation of the cell cycle by proteolysis. She returned to France in Marseille to work on the centrosome, primary cilia, cell cycle regulation and associated pathologies in Dr. Daniel Birnbaum’s laboratory at the CRCM.

Research Interest :

Dr. Claire Acquaviva and Dr. Emilie Mamessier co-lead a group at the CRCM interested on Circulating Tumor Cells (CTCs) and their contribution to cancer metastases. Their main research interest is focused on breast and colon cancers and aim at better defining CTCs at high risk of seeding metastases. For this, they are combining innovative technologies (single cells isolation, microfluidic …) with complex organoids generation, either as a source (tumoroid) or a receptacle (multicellular organoid) for CTCs.

OCM Member
Professor
Christian Medical College , India
Biography :

Dr. Murugan Ramalingam is Professor at the Centre for Biomaterials, Cellular & Molecular Theranostics, VIT University, India. He hss also Adjunct Professor at the Tohoku University, Japan and Professeur des Universite at the Faculté de Chirurgie Dentaire, Université de Strasbourg, France. He has worked at the WPI Advanced Institute for Materials Research, Japan, as an Assistant Professor. He has also worked at the National Institute of Standards and Technology (NIST) and the National Institutes of Health (NIH), under the U.S. National Academies Associateship program. He received his Ph.D. in Biomaterials from the CSIR-Central Leather Research Institute, University of Madras. He has also undergone training in Ethical and Policy issues on Stem Cells from Harvard University, USA, and in Operations Management from the University of Illinois-Chicago. His current research interests are focused on the development of multiphase biomedical materials, through conventional to nanotechnology to biomimetic approaches, microfabrication and bioprinting, cell patterning, stem cell differentiation, tissue engineering and drug delivery. He is the author of ~300 publications, including 20 textbooks relevant to nanotechnology, biomaterials, stem cells, tissue engineering and regenerative medicine. His current h-index is 40 with ~9400 citations. He has delivered several keynote/invited talks and has chaired/organized several international conferences related to Biomaterials, Bioprinting, Nanobiotechnology, Stem Cells and Tissue Engineering. He also serves as a board member of several international scientific and research committees in various public and private bodies and grant reviewer of various international funding agencies. He serves on the editorial boards of multiple biomaterials and tissue engineering-related journals, including the Editor-in-Chief of the Journal of Biomaterials and Tissue Engineering and the Journal of Bionanoscience. He is a recipient of several prestigious fellowships and awards, including CSIR Fellowship (India), Singapore Millennium Fellowship (SMF) (Singapore), NRC National Academies Fellowship (USA), Nationale Professeur des Universités (France), Fellow of Royal Society of Biology (UK), Fellow of Institute of Nanotechnology (UK) and Fellow of Royal Society of Chemistry (UK).

Research Interest :

Stem Cell Research,Tissue Engineering

OCM Member
Roswell Park Cancer Institute , USA
Biography :

Dean Tang, PhD, was trained as a Pathologist and is currently Professor & Chair in Department of Pharmacology & Therapeutics at Roswell Park Cancer Institute. His Master of Science thesis research (1986-1989), conducted in Dr. Hong-shen Tian’s laboratory in Wuhan University School of Medicine, focused on establishing lung cancer metastasis models. To continue his research on metastasis, Dr. Tang joined Dr. Ken Honn’s lab at Wayne State University (WSU) in 1989 to study the role of integrin receptors in mediating tumor cell – extracellular matrix interactions, tumor cell invasion, and tumor cell extravasation. Dr. Tang obtained his PhD in Cancer Biology in 1994 and stayed at WSU for a few years to explore apoptosis-based anti-prostate cancer therapeutics. In 1998, he was awarded a Burroughs-Wellcome Hitchings-Elion post-doctoral Fellowship to study oligodendrocyte precursor cell (OPC) development in Dr. Martin Raff’s lab in Medical Research Council (MRC) Laboratory for Molecular & Cellular Biology (LMCB) of University College London (UCL, UK). Dr. Tang returned to America in June of 2000 to join the MD Anderson Cancer Center Department of Epigenetics and Molecular Carcinogenesis till May of 2016.

Research Interest :

Dr. Tang and his colleagues have been studying cancer stem cells and cancer cell heterogeneity with a focus on prostate cancer. His career goals are to identify novel therapeutics and therapeutic combinations for personalized cancer treatment.

OCM Member
Professor
University of Iceland , Iceland
Biography :

Magnus S Magnusson, Research Professor. Ph.D. in 1983, University of Copenhagen. Author of the T-pattern model and the corresponding detection algorithms in the T-pattern detection and Analysis software THEMETM (PatternVision.com). He has focused on real-time organisation of behavior, co-directed DNA analysis, published numerous papers and given invited talks and keynotes at universities in Europe, USA and Japan and at international conferences in ethology, psychology, neuroscience, mathematical sciences, science of religion, proteomics and mass spectrometry. Deputy Director 1983-1988 in the Museum of Mankind, National Museum of Natural History, Paris. Repeatedly invited Professor in psychology and ethology (the biology of behavior) at the University of Paris, V, VIII and XIII. Since 1991, Founder and Director of the Human Behavior Laboratory (hbl.hi.is), University of Iceland. He works in collaboration between now 32 universities on Methodology for the Analysis of Social Interaction (MASI) initiated in 1995 at the Sorbonne, Paris based on “Magnusson’s analytical model

Research Interest :

Molecular Biology, Proteomics, Boinformatics, Mass Spectrometry, Genetics, Human Computer Interaction,

OCM Member
Chair, Chair
university of kansas , USA
Biography :

Dr. Heggeness completed his PhD at UC San Diego in membrane biology, and a postdoc at Rockefeller University in Virology. He received his MD from the University of Miami. After a residency in Orthopaedic Surgery, he completing a fellowship in Spine Surgery at the University of Toronto. He then joined the faculty at Baylor College of Medicine where he became Chairman of Orthopaedic Surgery in 2004. He moved take the Orthopaedic Surgery Chair at University of Kansas in Wichita in 2013. He has 84 publications and 4 issued patents.

Research Interest :

His interest has centered on intraosseous nerves, and recently, nerve derived stem cells.

Allied Academies Global Conference Directory

Mail us at

Program Enquiry
stemcell@alliedglobalevents.com
Sponsorship Opportunity
stemcell@alliedglobalevents.com
General Queries
stemcell@alliedevents.org
More details about sponsorship:sponsors@alliedacademies.com

Terms and Conditions

Responsibility
The organizers holds no responsibilities or liabilities of the personal articles of attendees at the venue against any kind of theft, lost, damage, due to any reason whatsoever. Delegates are entirely responsible for the safety of their own belongings.
Insurance
No insurance, of any kind, is included along with the registration in any of the events of the organization.
Transportation
Please note that transportation and parking is the responsibility of the registrant, Allied Academies will not be liable for any actions howsoever related to transportation and parking.
Press/Media
Press permission must be obtained from Allied Academies Conference Organizing Committee prior to the event. The press will not quote speakers or delegates unless they have obtained their approval in writing. The Allied Academies is an objective third-party nonprofit organization and this conference is not associated with any commercial meeting company.
Requesting an Invitation Letter
For security purposes, letter of invitation will be sent only to those individuals who had registered for the conference after payment of complete registration fee. 
Cancellation Policy
All cancellations or modifications of registration must be made in writing to stemcell@alliedglobalevents.com

If, due to any reason, Allied academies postpone an event on the scheduled date, the participant is eligible for a credit of 100% of the registration fee paid. This credit shall only be used for another event organized by Allied academies within period of one year from the date of rescheduling.

Postponement of event
If, due to any reason, Allied academies postpone an event and the participant is unable or unwilling to attend the conference on rescheduled dates, he/she is eligible for a credit of 100% of the registration fee paid. This credit shall only be used for another event organized by Allied academies within period of one year from the date of rescheduling.
Transfer of registration
All registrations, after payment of complete registration fee, are transferable to other persons from the same organization, if in case the person is unable to attend the event. Request for transfer of registration must be made by the registered person in writing to contacts@alliedacademies.com Details must include the full name of replaced new registrant, their title, contact phone number and email address. All other registration details will be assigned to the new person unless otherwise specified. Registration can be transferred to one conference to another conference of Allied academies if the person is unable to attend one of conferences.
However, Registration cannot be transferred if intimated within 14 days of respective conference.
The transferred registrations will not be eligible for Refund.
This cancellation policy was last updated on April 04, 2015.
Visa Information
Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible.
Allied academies will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only.
Important note for failed visa applications: Visa issues are not covered under the cancellation policy of Allied academies, including the inability to obtain a visa.
Refund Policy.
If the registrant is unable to attend, and is not in a position to transfer his/her participation to another person or event, then the following refund policies apply:
Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overhead charges, following Refund Policy
Orders are available:
  • Before 60 days of the conference: Eligible for Full Refund after deduction of $100 towards service Fee.
  • Within 60-30 days of Conference: Eligible for 50% of payment Refund.
  • Within 30 days of Conference: Not eligible for Refund.
  • E-Poster Payments will not be refunded
Accommodation Cancellation Policy
Accommodation Service Providers (Hotels) have their own cancellation policies which are applicable when cancellations are made less than 30 days prior to arrival. If in case the registrant wishes to cancel or amend the accommodation, he/ she is expected to inform the organizing authorities on a prior basis. Allied academies will advise the registrant to ensure complete awareness about the cancellation policy of your accommodation provider, prior to cancellation or modification of their booking.

Authorization Policy

Copyright © 2019-2020 Allied Academies, All Rights Reserved.